199 related articles for article (PubMed ID: 37660083)
21. Remodeling of Tumor Microenvironment by Tumor-Targeting Nanozymes Enhances Immune Activation of CAR T Cells for Combination Therapy.
Zhu L; Liu J; Zhou G; Liu TM; Dai Y; Nie G; Zhao Q
Small; 2021 Oct; 17(43):e2102624. PubMed ID: 34378338
[TBL] [Abstract][Full Text] [Related]
22. T-SIGn tumor reengineering therapy and CAR T cells synergize in combination therapy to clear human lung tumor xenografts and lung metastases in NSG mice.
Sonzogni O; Zak DE; Sasso MS; Lear R; Muntzer A; Zonca M; West K; Champion BR; Rottman JB
Oncoimmunology; 2022; 11(1):2029070. PubMed ID: 35154906
[TBL] [Abstract][Full Text] [Related]
23. BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity.
Hickman TL; Choi E; Whiteman KR; Muralidharan S; Pai T; Johnson T; Parikh A; Friedman T; Gilbert M; Shen B; Barron L; McGinness KE; Ettenberg SA; Motz GT; Weiss GJ; Jensen-Smith A
PLoS One; 2022; 17(5):e0266980. PubMed ID: 35507536
[TBL] [Abstract][Full Text] [Related]
24. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
25. Repolarization of Tumor-Infiltrating Myeloid Cells for Augmentation of CAR T Cell Therapies.
Luo W; Napoleon JV; Zhang F; Lee YG; Wang B; Putt KS; Low PS
Front Immunol; 2022; 13():816761. PubMed ID: 35250995
[TBL] [Abstract][Full Text] [Related]
26. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
Lindo L; Wilkinson LH; Hay KA
Front Immunol; 2020; 11():618387. PubMed ID: 33643299
[TBL] [Abstract][Full Text] [Related]
27. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D
Cells; 2023 Jun; 12(12):. PubMed ID: 37371075
[TBL] [Abstract][Full Text] [Related]
28. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
Tahmasebi S; Elahi R; Esmaeilzadeh A
Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
[TBL] [Abstract][Full Text] [Related]
29. Remodelling of tumour microenvironment by microwave ablation potentiates immunotherapy of AXL-specific CAR T cells against non-small cell lung cancer.
Cao B; Liu M; Wang L; Zhu K; Cai M; Chen X; Feng Y; Yang S; Fu S; Zhi C; Ye X; Zhang J; Zhang Z; Yang X; Zhao M; Wu Q; Xu L; Yang L; Lian H; Zhao Q; Zhang Z
Nat Commun; 2022 Oct; 13(1):6203. PubMed ID: 36261437
[TBL] [Abstract][Full Text] [Related]
30. CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape.
Rodriguez-Garcia A; Palazon A; Noguera-Ortega E; Powell DJ; Guedan S
Front Immunol; 2020; 11():1109. PubMed ID: 32625204
[TBL] [Abstract][Full Text] [Related]
31. Modulating tumor physical microenvironment for fueling CAR-T cell therapy.
Luo Z; Yao X; Li M; Fang D; Fei Y; Cheng Z; Xu Y; Zhu B
Adv Drug Deliv Rev; 2022 Jun; 185():114301. PubMed ID: 35439570
[TBL] [Abstract][Full Text] [Related]
32. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K
Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
[TBL] [Abstract][Full Text] [Related]
33. Involving stemness factors to improve CAR T-cell-based cancer immunotherapy.
Noraldeen SAM; Rasulova I; Lalitha R; Hussin F; Alsaab HO; Alawadi AH; Alsaalamy A; Sayyid NH; Alkhafaji AT; Mustafa YF; Shayan SK
Med Oncol; 2023 Oct; 40(11):313. PubMed ID: 37779152
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer.
Zhang Y; Liang K; Zhou X; Zhang X; Xu H; Dai H; Song X; Yang X; Liu B; Shi T; Wei J
Cancer Sci; 2023 Jul; 114(7):2798-2809. PubMed ID: 37151176
[TBL] [Abstract][Full Text] [Related]
35. Combining chemotherapy with CAR-T cell therapy in treating solid tumors.
Wang AX; Ong XJ; D'Souza C; Neeson PJ; Zhu JJ
Front Immunol; 2023; 14():1140541. PubMed ID: 36949946
[TBL] [Abstract][Full Text] [Related]
36. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
37. CAR T Cell Locomotion in Solid Tumor Microenvironment.
Nguyen DT; Ogando-Rivas E; Liu R; Wang T; Rubin J; Jin L; Tao H; Sawyer WW; Mendez-Gomez HR; Cascio M; Mitchell DA; Huang J; Sawyer WG; Sayour EJ; Castillo P
Cells; 2022 Jun; 11(12):. PubMed ID: 35741103
[TBL] [Abstract][Full Text] [Related]
38. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
Siegler EL; Wang P
Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
[TBL] [Abstract][Full Text] [Related]
39. Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy.
Li W; Pan X; Chen L; Cui H; Mo S; Pan Y; Shen Y; Shi M; Wu J; Luo F; Liu J; Li N
Front Immunol; 2023; 14():1186383. PubMed ID: 37342333
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of CAR-T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins.
Qiao Y; Chen J; Wang X; Yan S; Tan J; Xia B; Chen Y; Lin K; Zou F; Liu B; He X; Zhang Y; Zhang X; Zhang H; Wu X; Lu L
Cancer Commun (Lond); 2023 Jul; 43(7):788-807. PubMed ID: 37282786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
